Johnson & Johnson

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 01:30:02 18/04/2026 am IST			5-day change	1st Jan Change
234.18 ^USD	-0.15%		-2.95%	+13.16%

17/04	Moberg Pharma proposes Lars Johansson as new Chairman	FW
16/04	MeiraGTx Acquires Bota-vec From Johnson & Johnson; Reports Positive Three-Year Early-Stage Data From AAV-hAQP1 Program in Xerostomia	MT

Johnson & Johnson Reports Q2 Worldwide Sales of Cancer Drug Darzalex

Published on 07/16/2025 at 04:35 pm IST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Johnson & Johnson

17/04	Moberg Pharma proposes Lars Johansson as new Chairman	FW
16/04	MeiraGTx Acquires Bota-vec From Johnson & Johnson; Reports Positive Three-Year Early-Stage Data From AAV-hAQP1 Program in Xerostomia	MT
16/04	US FDA's accelerated approval for drugs needs more transparency, says research firm	RE
16/04	Daiwa Securities Adjusts PT on Johnson & Johnson to $246 From $237, Maintains Outperform Rating	MT
16/04	Argus Research Adjusts PT on Johnson & Johnson to $275 From $240, Maintains Buy Rating	MT
15/04	Argus Raises Price Target on Johnson & Johnson to $275 From $240	MT
15/04	BofA Securities Raises Price Target on Johnson & Johnson to $254 From $253, Maintains Neutral Rating	MT
15/04	Johnson & Johnson Reported Above-Peer Topline Growth in Q1, BofA Says	MT
15/04	BofA Securities Raises Price Target on Johnson & Johnson to $254 From $253, Maintains Neutral Rating	MT
15/04	Johnson & Johnson Q1 Reinforces Growth Outlook on New Product Cycle, Morgan Stanley Says	MT
15/04	Johnson & Johnson Highlights Pipeline Catalysts, Reaffirms Growth Outlook After Q1 Beat, RBC Says	MT
15/04	Kimberly-Clark retains Urdaneta as CFO of combined company after $40-billion Kenvue deal	RE
15/04	RBC Raises Price Target on Johnson & Johnson to $265 From $255, Keeps Outperform Rating	MT
15/04	Morgan Stanley Lifts Price Target on Johnson & Johnson to $283 From $267, Maintains Overweight Rating	MT
15/04	Stifel Adjusts Price Target on Johnson & Johnson to $250 From $220, Maintains Hold Rating	MT

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (64.1%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (35.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; At the end of 2025, Johnson & Johnson has 63 manufacturing facilities located in the United States (22), North America (7), Europe (22), Africa and Asia/Pacific (12). The United States accounts for 57.1% of net sales.

Employees

1,38,200

Sector

Pharmaceuticals

Calendar

26/05 - Ex-dividend date - 1.34 USD

More about the company